Our mission is to develop new, anticancer drugs using genomic selection to identify potential patient responses prior to treatment. This approach will change today’s “one-size-fits-all” clinical paradigm and allow a choice of optimized treatments for individual patients. We believe that our genomic approach has the potential to significantly increase the efficacy of cancer treatments and, thus, improve clinical outcomes.